Successful treatment of ulerythema ophryogenes with pulsed dye laser: a case report
- PMID: 40761190
- PMCID: PMC12319604
- DOI: 10.21037/acr-24-215
Successful treatment of ulerythema ophryogenes with pulsed dye laser: a case report
Abstract
Background: Ulerythema ophryogenes (UO) is a rare cutaneous disorder characterized by inflammatory keratotic papules that primarily affect the face. This clinical case may enrich and provide an interesting literature overview on the laser therapy for UO, which represents a rare skin illness difficult to treat.
Case description: A 25-year-old female patient having an UO family history and who presented a progressive erythema and confluent horny follicular erythematous papules with areas of alopecia around the lateral third of eyebrows without signs of pitted or atrophic scars, which has been evident since childhood, underwent to a single session of dye laser. She was complaining of discomfort in the involved skin areas. The patient had not been taking any medications prior to laser therapy. The use of anaesthetic was avoided. After only one therapy session of dye laser the result was clinically optimal. A visible reduction in roughness and a partial hair regrowth in the treated area were observed at 2 months follow-up after treatment. The horn plugs were no longer evident, and the erythema had subsided. The hairs had become thicker, darker, and more numerous, covering most of the underlying dermatitis. Following the laser procedure, the patient didn't experience complications or severe adverse reactions.
Conclusions: Pulsed dye laser treatment appears to be a safe and effective treatment for the erythema and alopecia symptoms associated with this refractory condition.
Keywords: Ulerythema ophryogenes (UO); case report; pulsed dye laser (PDL).
Copyright © 2025 AME Publishing Company. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://acr.amegroups.com/article/view/10.21037/acr-24-215/coif). I.F. and T.Z. report that they were employed by El.En. Group. The other authors have no conflicts of interest to declare.
Figures


Similar articles
-
Severe Relapsing Hailey-Hailey Disease Displaying a Durable Complete Response to Hydroxyurea.Acta Dermatovenerol Croat. 2024 Nov;32(3):168-169. Acta Dermatovenerol Croat. 2024. PMID: 40654217
-
Laser therapy for treating hypertrophic and keloid scars.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD011642. doi: 10.1002/14651858.CD011642.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161591 Free PMC article.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
A Case of Idiopathic Follicular Mucinosis Treated Successfully with Cyclosporine.Acta Dermatovenerol Croat. 2024 Dec;32(4):210-211. Acta Dermatovenerol Croat. 2024. PMID: 40657655
References
-
- Morton CM, Bhate C, Janniger CK, et al. Ulerythema ophryogenes: updates and insights. Cutis 2014;93:83-7. - PubMed
Publication types
LinkOut - more resources
Full Text Sources